Douglas Dias E Silva, Bruna Bianca Lopes David, Veridiana Pires de Camargo, Renee Zon Filipi, María Lucila González Donna, Juan Carlos Haro Varas, Rodrigo Ramella Munhoz, Maycos L Zapata, Cicero Luiz Cunha Martins, Matias Chacon, Rafael Schmerling, Reynaldo Jesus Garcia, Roberto Carmagnani Pestana
{"title":"拉丁美洲罕见癌症和肉瘤政策和肉瘤药物批准的评估：来自LACOG肉瘤组的报告。","authors":"Douglas Dias E Silva, Bruna Bianca Lopes David, Veridiana Pires de Camargo, Renee Zon Filipi, María Lucila González Donna, Juan Carlos Haro Varas, Rodrigo Ramella Munhoz, Maycos L Zapata, Cicero Luiz Cunha Martins, Matias Chacon, Rafael Schmerling, Reynaldo Jesus Garcia, Roberto Carmagnani Pestana","doi":"10.1200/GO.24.00239","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The availability of drugs and national public policies for patients with rare cancers, including sarcomas, varies in different parts of the world.</p><p><strong>Methods: </strong>In this manuscript, we have conducted a comprehensive analysis to evaluate rare cancer policies in Latin American countries' national policy documents. Additionally, we have reviewed the approvals for sarcoma drugs in selected Latin American countries and compared them with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals.</p><p><strong>Results: </strong>The documents reviewed showed a lack of explicit focus on rare cancers, with no mention in 70% of the countries analyzed. Drug approval data reveal that in the last 15 years, the FDA and EMA have approved 19 and 13 drugs for sarcoma, whereas their Latin American counterparts, namely ANVISA, ANMAT, and COFEPRIS, approved six, eight, and seven drugs, respectively.</p><p><strong>Conclusion: </strong>Our data suggest that improving rare cancer and sarcoma care in Latin America requires enhanced collaboration for better rare cancer policies.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400239"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Assessment of Rare Cancers and Sarcoma Policy and Sarcoma Drug Approvals in Latin America: A Report From the LACOG Sarcoma Group.\",\"authors\":\"Douglas Dias E Silva, Bruna Bianca Lopes David, Veridiana Pires de Camargo, Renee Zon Filipi, María Lucila González Donna, Juan Carlos Haro Varas, Rodrigo Ramella Munhoz, Maycos L Zapata, Cicero Luiz Cunha Martins, Matias Chacon, Rafael Schmerling, Reynaldo Jesus Garcia, Roberto Carmagnani Pestana\",\"doi\":\"10.1200/GO.24.00239\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The availability of drugs and national public policies for patients with rare cancers, including sarcomas, varies in different parts of the world.</p><p><strong>Methods: </strong>In this manuscript, we have conducted a comprehensive analysis to evaluate rare cancer policies in Latin American countries' national policy documents. Additionally, we have reviewed the approvals for sarcoma drugs in selected Latin American countries and compared them with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals.</p><p><strong>Results: </strong>The documents reviewed showed a lack of explicit focus on rare cancers, with no mention in 70% of the countries analyzed. Drug approval data reveal that in the last 15 years, the FDA and EMA have approved 19 and 13 drugs for sarcoma, whereas their Latin American counterparts, namely ANVISA, ANMAT, and COFEPRIS, approved six, eight, and seven drugs, respectively.</p><p><strong>Conclusion: </strong>Our data suggest that improving rare cancer and sarcoma care in Latin America requires enhanced collaboration for better rare cancer policies.</p>\",\"PeriodicalId\":14806,\"journal\":{\"name\":\"JCO Global Oncology\",\"volume\":\"11 \",\"pages\":\"e2400239\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCO Global Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1200/GO.24.00239\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Global Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/GO.24.00239","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Assessment of Rare Cancers and Sarcoma Policy and Sarcoma Drug Approvals in Latin America: A Report From the LACOG Sarcoma Group.
Purpose: The availability of drugs and national public policies for patients with rare cancers, including sarcomas, varies in different parts of the world.
Methods: In this manuscript, we have conducted a comprehensive analysis to evaluate rare cancer policies in Latin American countries' national policy documents. Additionally, we have reviewed the approvals for sarcoma drugs in selected Latin American countries and compared them with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals.
Results: The documents reviewed showed a lack of explicit focus on rare cancers, with no mention in 70% of the countries analyzed. Drug approval data reveal that in the last 15 years, the FDA and EMA have approved 19 and 13 drugs for sarcoma, whereas their Latin American counterparts, namely ANVISA, ANMAT, and COFEPRIS, approved six, eight, and seven drugs, respectively.
Conclusion: Our data suggest that improving rare cancer and sarcoma care in Latin America requires enhanced collaboration for better rare cancer policies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
